全文获取类型
收费全文 | 247篇 |
免费 | 32篇 |
国内免费 | 19篇 |
专业分类
基础医学 | 1篇 |
临床医学 | 41篇 |
内科学 | 90篇 |
神经病学 | 7篇 |
特种医学 | 10篇 |
外科学 | 3篇 |
综合类 | 77篇 |
预防医学 | 2篇 |
药学 | 62篇 |
中国医学 | 4篇 |
肿瘤学 | 1篇 |
出版年
2024年 | 2篇 |
2023年 | 5篇 |
2022年 | 2篇 |
2021年 | 16篇 |
2020年 | 15篇 |
2019年 | 8篇 |
2018年 | 7篇 |
2017年 | 11篇 |
2016年 | 8篇 |
2015年 | 15篇 |
2014年 | 26篇 |
2013年 | 27篇 |
2012年 | 29篇 |
2011年 | 19篇 |
2010年 | 32篇 |
2009年 | 20篇 |
2008年 | 17篇 |
2007年 | 14篇 |
2006年 | 4篇 |
2005年 | 2篇 |
2004年 | 9篇 |
2003年 | 3篇 |
2002年 | 3篇 |
2001年 | 1篇 |
2000年 | 1篇 |
1999年 | 2篇 |
排序方式: 共有298条查询结果,搜索用时 15 毫秒
1.
2.
目的探讨急诊经皮冠状动脉介入治疗(PCI)术应用国产替罗非班对糖尿病ST段抬高急性心肌梗死(AMI)病人支架植入术后再狭窄的影响。方法104例首发ST段抬高AMI且有糖尿病并接受急诊PCI治疗的病人,随机分为替罗非班组(n=51)和常规治疗组(n=53),替罗非班组病人诊断后即刻给予替罗非班氯化钠注射液10μg·kg~(-1)于3 min内推注完毕,术后替罗非班0.15μg·kg~(-1)·min~(-1)滴注24~36h,其余治疗同常规治疗组。均于术后6mo复查冠状动脉造影,了解支架内再狭窄的发生情况。结果与常规治疗组比较,替罗非班组术后6 mo支架再狭窄发生率减少(18%vs 10%),差异有显著意义(P<0.05)。结论替罗非班可降低糖尿病并ST段抬高急性心肌梗死病人急诊经皮冠状动脉介入治疗术后支架再狭窄的发生。 相似文献
3.
目的比较替罗非班与氯吡格雷对不稳定性心绞痛患者的治疗效果。方法选取不稳定性心绞痛患者126例,随机分为替罗非班组和氯吡格雷组各63例,两组均在应用阿司匹林和普通肝素的基础上分别给予替罗非班和氯吡格雷治疗5天,测定治疗前后各组的血液流变学指标并比较两组的临床效果。结果替罗非班组临床效果优于氯吡格雷组,差别有统计学意义(P<0.05)。结论替罗非班对不稳定性心绞痛疗效确切,通过改变血液流变学指标而改善患者预后。 相似文献
4.
目的评估替罗非班对急性ST段抬高心肌梗死(STEMI)患者梗死相关动脉自发再通、经皮冠状动脉介入治疗(PCI)后心肌灌注及住院期预后的影响。方法连续入选316例急性STEMI患者,随机决定急诊室给予替罗非班(156例)与否(160例)。根据急诊冠脉造影结果分为TMP 0~1级组(218例)和TMP 2~3级组(98例)。所有TMP 0~1级患者均行紧急PCI,据替罗非班的应用情况分为替罗非班亚组(91例)与常规治疗亚组(127例)。分析替罗非班与梗死相关动脉自发再通、PCI术后心肌灌注、住院期主要心脏不良事件(MACE)的关系。结果 TMP 2~3级组甘油三酯、白细胞升高显著低于TMP 0~1级组(P〈0.05),且替罗非班的应用比例显著高于TMP 0~1级组(P〈0.01)。亚组分析表明,替罗非班组PCI术后即刻校正的TIMI桢数、住院时间、TMP 0~2级及住院期MACE发生率均降低(P〈0.05),左室射血分数增高(P〈0.05);高龄、替罗非班治疗、左室射血分数降低、术后TMP0~2级与住院期MACE发生率相关(P〈0.05)。结论早期应用替罗非班可增加急性STEMI患者梗死相关动脉自发再通率,改善急诊PCI术后梗死区域心肌再灌注与住院期临床预后。 相似文献
5.
目的 探究冠状动脉内应用重组人尿激酶原对ST段抬高型心肌梗塞(STEMI)患者冠状动脉微循环再灌注水平的影响.方法 将2018年6月至2020年5月我院急诊收治的84例高血栓负荷STEMI患者随机分为对照组44例和试验组40例.对照组在冠状动脉介入术(PCI)中经血栓抽吸后冠状动脉内应用血小板GPIIb/IIIa受体阻... 相似文献
6.
目的 探讨替罗非班对氧化型低密度脂蛋白(ox-LDL)诱导的脐静脉内皮细胞(EA.hy926)损伤的影响和可能机制.方法 采用低、中、高剂量的替罗非班作用于ox-LDL诱导的EA.hy926细胞,采用细胞计数法(CCK-8)、流式细胞术分别检测细胞活力和凋亡.实时荧光定量PCR(qRT-PCR)检测miR-22表达水平... 相似文献
7.
目的:观察替罗非班联合血栓抽吸对急性ST段抬高型心肌梗死(STEMI)行急诊PCI患者的近期疗效。方法:选择行急诊PCI术的STEMI患者68例,梗死相关血管(IRA)血流TIMI 0-1级。其中37例行替罗非班联合血栓抽吸(血栓抽吸组),另外31例经传统方法完成PCI术(传统PCI组)。比较两组患者IRA的TIMI血流分级、无复流/慢血流发生率、术中术后并发症及术后30 d内主要心脏不良事件(MACE)发生率。结果:与传统PCI组相比,血栓抽吸组再灌注心律失常、出血、血肿等术中及术后并发症并没有减少(P〉0.05)。但血栓抽吸组IRA术后TIMI血流分级明显高于传统PCI组(P〈0.05),无复流/慢血流发生率、球囊使用例数及术后30 d部分MACE发生率低于传统PCI组,差异有统计学意义(P〈0.05)。结论:替罗非班联合血栓抽吸能够改善STEMI患者急诊PCI术后IRA血流,降低无复流/慢血流现象及近期MACE的发生率,显著改善STEMI患者的近期预后。 相似文献
8.
《The Egyptian Heart Journal》2014,66(3):251-257
BackgroundGlycoprotein IIb/IIIa inhibitor therapy during primary percutaneous coronary intervention (PCI) decreases the incidence of major adverse cardiac events.AimTo study the impact of high bolus dose tirofiban on left ventricular ejection fraction in patients with acute anterior ST segment elevation MI treated with primary PCI.Patients and methodsForty patients presenting to Ain Shams University, and specialized hospitals with the diagnosis of acute anterior STEMI were treated with primary PCI. Twenty patients were given conventional intravenous bolus dose tirofiban (10 μg/kg) upstream prior to primary angioplasty and twenty patients were given intravenous high bolus dose tirofiban (25 μg/kg) upstream prior to PCI. In-hospital follow up was done including echocardiography, and serial cardiac enzymes in addition to clinical follow up for MACE and bleeding complications.ResultsSuccessful primary angioplasty was attained in all patients. The LV systolic function was significantly better in the high bolus dose group in comparison to the conventional bolus dose groups (48% vs 41%, P < 0.01). The incidence of recurrent ischemia was statistically non-significant between the two groups (5% vs 25%, P > 0.05). Both regimens were safe and the bleeding complications were minimal and did not differ between the study groups.ConclusionIn patients presenting with acute anterior STEMI and treated with primary PCI, the high bolus dose tirofiban given intravenously upstream prior to PCI seems to be a safe and effective regimen to achieve a better left ventricular ejection fraction in comparison to the conventional bolus dose regimen, without increasing the risk of bleeding. 相似文献
9.
Rationale:Systemic lupus erythematosus (SLE) is an important cause of stroke, more than a half the cases present as acute ischemic stroke. Thrombolysis is an effective choice in most cases, but for large vessel occlusion, mechanical thrombectomy is more effective. Here we reported a case of SLE-related stroke with left middle cerebral artery (MCA) occlusion, who was successfully treated by MT and tirofiban.Patient concern:A 38-year-old female suffered from right hemiplegia and aphasia for 8 hours. She was diagnosed with SLE 20 years ago, and neuropsychiatric SLE was considered 8 months before this onset. One month ago, glucocorticoids were discontinued by herself because of deterioration of bilateral femoral head osteonecrosis.Diagnosis:Left MCA occlusion was confirmed by computed tomography perfusion.Intervention:Immediate mechanical thrombectomy was performed and tirofiban was given to prevent re-occlusion of left MCA. Twenty fourhours later oral antiplatelet was given after intracranial hemorrhage was ruled out.Outcomes:Her neurological symptom improved several days later, and she was transferred to further rehabilitation. At 4 months follow-up she can live independently with mild hypophrasia. There was no further events of ischemic stroke in 1-year follow-up.Lessons:Mechanical thrombectomy is a highly effective and indispensable treatment for SLE related large vessel occlusion. In addition, tirofiban may reduce vessel reocclusion in special cases such as SLE and artery stenosis. 相似文献
10.
Cohen M Maritz F Gensini GF Danchin N Timerman A Huber K Gurfinkel EP White H Fox KA Vittori L Le-Louer V Bigonzi F 《Journal of thrombosis and thrombolysis》2000,10(3):241-246
Patients with acute myocardial infarction (AMI) who do not receive early reperfusion therapy are at high risk of reinfarction or death, and the efficacy and safety of antithrombotic therapy in this group of patients has not been evaluated. Enoxaparin is a low-molecular-weight heparin (LMWH) that has previously been shown to reduce the incidence of ischemic events in patients with unstable angina or non–Q-wave MI. The principal aims of the TETAMI study are to investigate the efficacy and safety of treatment with enoxaparin or tirofiban (a glycoprotein IIb/IIIa receptor antagonist) alone or in combination for 2 to 8 days in patients with AMI who are not eligible for early reperfusion therapy. In this 2 by 2 factorial design study approximately 900 patients will be randomly assigned, in a blinded manner, to one of four treatments: enoxaparin alone, enoxaparin plus tirofiban, unfractionated heparin (UFH), or UFH plus tirofiban, with appropriate matched placebos. The primary end point is the composite of death, recurrent AMI, and recurrent angina, analyzed at 30 days after AMI. The design and methods of the TETAMI study are described in this article. 相似文献